| Outcome Measures: |
Primary: Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c., Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months, 0-26 weeks | Secondary: Change in Total Daily Dose of Insulin (TDI) Per kg, 0-26 weeks|Change in Body Mass Index (BMI), 0-26 weeks|Change in Waist Circumference, 0-26 weeks|Change in Body Composition, Change in percent body fat, 0-26 weeks|Change in Serum Lipids, 0-26 weeks|Change in Blood Pressure, 0-26 weeks | Other: Change in Liver Enzymes and Serum Creatinine, 0-26 weeks|Frequency of Severe Hypoglycemia, 26 weeks|Frequency of Diabetic Ketoacidosis, 26 weeks|Frequency of Gastrointestinal Side-effects Including Stomach Discomfort, Diarrhea, Nausea/Vomiting, Indigestion, Flatulence., 26 weeks|Frequency of Lactic Acidosis, 26 weeks|Change in Adipocytokines, 0-26 weeks|Change in Androgen Levels in Females, 0-26 weeks|Change in C-peptide, Measured with mixed meal tolerance test among participants with evidence of residual C-peptide on a non-fasting C-peptide at screening, 0-26-weeks|Change in Vascular Dysfunction, 0-26 weeks
|
